Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Rating Wk chg 3/16 cls
Adventrx (ANX) ThinkEquity Vinny Jindal New Buy -5% $1.98
Jindal set a $5 target. He sees the company's CoFactor (ANX-510) as a potential target for partnering, and expects results from a Phase IIb trial comparing the compound to leucovorin in metastatic colorectal cancer in 2H07. The folate-based active metabolite of leucovorin is also in Phase III testing for metastatic colorectal cancer and in Phase II for advanced breast

Read the full 818 word article

How to gain access

Continue reading with a
two-week free trial.